Clinical Trials Logo

Mitral Disease clinical trials

View clinical trials related to Mitral Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05479188 Recruiting - Clinical trials for Coronary Artery Disease

Comparative Analysis of the Microcirculation During Cardiac Surgery With Minimal Invasive Versus Conventional Extracorporeal Circulation

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

The aim of the proposed study is to evaluate microcirculatory alterations in patients undergoing open heart surgery with minimal invasive versus conventional extracorporeal circulation. Positive clinical results evidenced with goal-directed perfusion and cerebral oximetry monitoring could be attributed to preserved microcirculation at tissue level.

NCT ID: NCT04464876 Active, not recruiting - Clinical trials for Mitral Regurgitation

SATURN Transcatheter Mitral Valve Replacement for Functional Mitral Regurgitation

Start date: August 19, 2020
Phase: N/A
Study type: Interventional

This study is a prospective, single-arm, multi-center feasibility clinical study of the SATURN TA System for the treatment of NYHA Class ≥ II patients with severe functional mitral regurgitation who are not suitable for surgical treatment following Heart Team assessment.

NCT ID: NCT03661398 Active, not recruiting - Clinical trials for Mitral Regurgitation

Caisson Transcatheter Mitral Valve Replacement (TMVR)

INTERLUDE
Start date: July 20, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the safety and performance of Transcatheter Mitral Valve Replacement (TMVR) system for the treatment of severe, symptomatic mitral regurgitation (MR).

NCT ID: NCT03230747 Active, not recruiting - Clinical trials for Mitral Regurgitation

SAPIEN M3 EFS: Early Feasibility Study of the Edwards SAPIEN M3 System for the Treatment of Mitral Regurgitation

SAPIEN M3 EFS
Start date: September 14, 2017
Phase: N/A
Study type: Interventional

This study will evaluate the safety and functionality of the SAPIEN M3 System in patients with symptomatic, severe MR and will provide guidance for future clinical study designs utilizing the SAPIEN M3 System.